Best Dermatology Companies in Massachusetts, United States
The 35 best Dermatology companies in Massachusetts, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Third Harmonic Bio.
Ranked: Best Dermatology companies in Massachusetts
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Third Harmonic Bio Developer therapeutics to treat allergy and inflammatory diseases | $205M | 55 mo ago | 28 | Natalie Holles Chief Executive Officer | WordPressApple iCloud MailMicrosoft 365+17 | — | — |
| 2 | Alys Pharmaceuticals Developer of therapeutics for immuno-dermatological conditions | $100M | 31 mo ago | — | Thibaud Portal Founder | — | — | — |
| 3 | Cynosure Developer of energy-based aesthetic and medical treatment systems | $87M | 50 mo ago | 669 669 → 827 (+24%) | Michael Davin CEO | WordPressSentryApple iCloud Mail+29 | 275 patents Non‑invasive RF, microwave and laser aesthetic devices for skin tightening and liposuction | — |
| 4 | Cytrellis Developer of aesthetic devices for scar reduction and skin tightening | $86M | 21 mo ago | 59 59 → 59 (+0%) | Jason Richey President & Chief Executive Officer | WordPressApple iCloud MailMySQL+13 | — | 1 internship |
| 5 | DermBiont Developer of microbial therapeutics designed to treat skin diseases | $73M | 35 mo ago | 36 | Nichola Eliovits Co-Founder | Squarespace CommerceSquarespaceTypeScript+16 | 49 patents Topical pharmaceutical formulations delivering PK/AKT inhibitors for skin disease therapy. | — |
| 6 | Pyramid Bio Developer of small molecules for the treatment of dermatology and cancer | $71M | 59 mo ago | 3 | — | — | — | — |
| 7 | DeepCure Developer of novel small molecule therapies for immune diseases | $65M | 29 mo ago | — | Thrasyvoulos Karydis Co-Founder & CTO | Cart FunctionalitySquarespace CommerceSquarespace+12 | 10 patents AI-driven drug discovery and automated chemical synthesis workflow optimization | — |
| 8 | NFlection Developer of targeted topical therapies for rare disorders | $45M | 38 mo ago | 6 | Scott Plotkin Co-Founder | — | — | — |
| 9 | DUSA Pharma Dermatology products for actinic keratosis and acne. | $43M | 318 mo ago | 177 | Robert Doman CEO & President | — | — | — |
| 10 | AOBiome Therapeutics company restoring immune functionality to treat inflammatory skin conditions | $34M | 116 mo ago | 8 | David Whitlock Co-Founder | WordPressMySQLPHP+17 | 264 patents Microbiome-based ammonia‑oxidizing bacterial therapeutics for skin, nasal, ocular, auditory, and urogenital health | — |
| 11 | Aldena Therapeutics Developer of gene therapies for dermatological conditions | $30M | 40 mo ago | — | Thibaud Portal CEO | — | — | — |
| 12 | AVAVA Platform offering intradermal energy solutions for skin treatments | $25M | 7 mo ago | 1 | Irina Erenburg CEO | WordPressApple iCloud MailMicrosoft 365+30 | 158 patents Medical laser treatment devices with real‑time feedback and motion‑tracking systems | 1 job opening |
| 13 | Concerto Biosciences Developer of microbe-based products for agriculture and human health | $25M | 50 mo ago | 30 | Jared Kehe Co-Founder | — | — | — |
| 14 | Follica Regenerative platform pioneering innovative hair growth solutions | $24M | 190 mo ago | 7 | Jason Bhardwaj CEO | — | 80 patents Microneedle scalp devices delivering hair-growth compounds for alopecia treatment | — |
| 15 | Silk Therapeutics Clean, anti-aging skincare using activated silk technology for balanced skin | $23M | 109 mo ago | 75 | — | — | — | — |
| 16 | Sofregen Natural biomaterials for soft tissue regeneration in aesthetic and surgical procedures | $19M | 84 mo ago | 8 | Anh Hoang Co-Founder & CSO | — | — | — |
| 17 | Magen BioSciences Empowering individuals with personalized care for optimal health and well-being | $17M | 244 mo ago | 16 | Brian Gallagher CEO | — | — | — |
| 18 | Blossom Innovations Developer of smart devices for treating multiple skin diseases | $9M | 111 mo ago | 4 | Henry Chan Founder | — | 58 patents Optical-based selective tissue ablation and diagnostic analysis for minimally invasive therapies | — |
| 19 | MoMelan Technologies Labeling solutions provider specializing in diverse industries with advanced printing technology | $9M | 182 mo ago | 18 | Sameer Sabir CEO & President | — | 52 patents Microblister skin graft harvesting and application devices for dermatological transplantation | — |
| 20 | Shaser Laser and light-based aesthetic medical devices | $8M | 198 mo ago | 15 | Steven M. Fraundorfer CEO | — | 104 patents Provides power supplies and control systems for light-based dermatological treatment devices. | — |
| 21 | Oasis Pharmaceuticals Developer of therapeutics to treat inflammatory, fibrotic, and metabolic disorders | $2M | 16 mo ago | — | Lidija Covic Founder & CSO | — | — | — |
| 22 | Caliber I.D. Provider of screening device for dermatologist | $1M | 83 mo ago | 18 18 → 16 (-11%) | — | — | 36 patents Off‑road vehicle traction and loading accessories for snowmobiles and tracked machines | — |
| 23 | Niraskin Provider of at-home laser skincare devices for anti-aging. | $25K | 4 mo ago | 11 | — | Cart FunctionalityShopifyAmazon Web Services+42 | — | — |
| 24 | Algeness Developer of bio-technologies in aesthetic medical field | — | 83 mo ago | 5 | Doug Abel CEO | PHPVimeoBootstrap+8 | — | — |
Top 12 Dermatology companies in Massachusetts
#1
Series B · Waltham, Massachusetts · founded 2016 · 1 employees$25.2Mraised▾
Platform offering intradermal energy solutions for skin treatments. It provides aesthetic treatments aim to address skin pigmentation issues and rejuvenate skin color. It utilize imaging and artificial intelligence to create personalized treatment plans for patients.
- Feb 2026Series B$19.6M
- Apr 2024Series B$25.2M
#2
Series C · Boston, Massachusetts · founded 2012 · 59 employees$86.1Mraised▾
Cytrellis is a clinical-stage med-tech company developing a proprietary class of aesthetic devices for dermatology, scar-reduction, and aesthetic-medicine. Its proprietary technology can tighten and manipulate skin without surgery and removes sagging skin associated with aging without surgery or scarring, enabling aesthetic practitioners to improve age-related changes in the skin. It is working with physicians and partners to develop product solutions that emphasize safety, clinical results, and improved quality of life.
- Dec 2024Series C$25.1M
- Jan 2021Series C$50M
- Jun 2018Series B$28.5M
- Apr 2016Series A—
#3
Seed · Boston, Massachusetts · founded 2024$100Mraised▾
Developer of therapeutics for immuno-dermatological conditions. The company harnesses cutting edge-science and technologies to develop a pipeline of programs and platforms targeting multiple dermatological indications such as atopic dermatitis, vitiligo, alopecia areata and chronic spontaneous urticaria.
- Feb 2024Seed$100M
#4
Series A · Boston, Massachusetts · founded 2018$64.6Mraised▾
Developer of novel small molecule therapies for immune diseases. This company utilizes an automated chemical synthesis platform to discover and develop treatments for autoimmune disorders. Their pipeline includes preclinical and clinical-stage candidates targeting various immune-mediated conditions. The company collaborates with leading researchers to advance its therapeutic approach.
- Apr 2024Series A$24.6M
- Nov 2021Series A$40M
#5
Funding Raised · Boston, Massachusetts · founded 2013$2Mraised▾
Oasis Pharmaceuticals is a developer of therapeutic agents for inflammatory, fibrotic and metabolic disorders. The products developed are OA-235i to treat NASH (in phase I), OA-3 hydrogel to treat AD/pruritus (in phase I), and OA-235c to treat IPF (in preclinical stage).
- May 2025Grant (prize money)$2M
#6
Series B · Melrose, Massachusetts · founded 2015 · 36 employees$73.3Mraised▾
Developer of microbial therapeutics designed to treat skin diseases. The topical therapeutic candidates include DBI-001 for eczema, athlete's foot, and nail fungus, DBI-002 for inflammatory dandruff, and SM-020 for benign skin tumors.
- Oct 2023Series B$32.7M
- Mar 2023Conventional Debt$4.7M
- Sep 2022Conventional Debt$2.5M
- Dec 2021Series A$28M
#7
Public · Cambridge, Massachusetts · founded 2019 · 28 employees$205Mraised▾
Developer therapeutics to treat allergy and inflammatory diseases. The company's product line include THB001 is an oral small-molecule KIT inhibitor for the treatment of severe allergic and mast cell-driven inflammatory conditions like Chronic Inducible Urticaria, airway, and gastrointestinal tract indications.
- Feb 2022Series B$155M
- 2019Series A$50M
- Jan 2019Seed—
#8
Series A · Boston, Massachusetts · founded 2013 · 6 employees$45.4Mraised▾
Developer of targeted topical therapies for rare disorders. It offers mitogen-activated protein kinase inhibitors to treat cutaneous neurofibromas in neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, congenital birthmarks, and other RAS-mediated skin conditions.
- Jul 2023Series A$4M
- Jun 2022Series A$20M
- Apr 2020Series A$20M
- Jan 2017Seed$1.4M
#9
Seed · Danvers, Massachusetts · founded 2012 · 11 employees$25Kraised▾
{}
- Apr 2026Seed$25K
#10
Acquired · Westford, Massachusetts · founded 1991 · 669 employees$86.9Mraised▾
Developer of energy-based aesthetic and medical treatment systems. It focuses on developin aesthetic and gynecologic laser and radiofrequency technologies for a diverse range of leading treatment applications for hair removal, skin revitalization, scar reduction, gynecological health, body contouring, and more.
- Jul 2022Post IPO$26.7M
- May 2022Post IPO$60M
- Dec 2019Post IPO—
- Mar 2018Unattributed$180K
#11
Series C · Waltham, Massachusetts · founded 2015 · 3 employees$71.2Mraised▾
Pyramid Bio is developing small molecules for the treatment of dermatology and oncology disorders. The company's lead candidate, PBI-100 is a selective TRK modulator and has anti-inflammatory and antiproliferative effects. This molecule is being developed for psoriasis and atopic dermatitis (phase 1). Another candidate, PBI-200 is a TRK inhibitor and being developed for the treatment of various solid and liquid tumors.
- Oct 2021Series C$33.5M
- Aug 2020Series B$28M
- Jul 2020Series B$6M
- Jul 2018Series A$17.3K
#12
Series B · Boston, Massachusetts · founded 2021$30Mraised▾
Developer of gene therapies for dermatological conditions. It offers small interfering RNAs-based therapeutics for atopic dermatitis, vitiligo, alopecia areata, psoriasis and other inflammatory diseases.
- Apr 2023Grant (prize money)—
- Mar 2023Series B$30M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Dermatology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.